Pfizer and its partner BioNTech announced plans to apply for FDA emergency use authorization for their vaccine candidate, after test results showed it was 95% effective at preventing COVID-19. CBS News’ Danya Bacchus reports, and then New York Times’ “Matter” columnist Carl Zimmer joins CBSN’s “Red & Blue” anchor Elaine Quijano to discuss the impact of the coming vaccines.
